Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype Oxford Asthma Attack Risk Scale (ORACLE)
Reduction of the risk of severe asthma attacks is a major goal of current guidelines [1]. The observation that blood eosinophils and exhaled nitric oxide fraction ( F ENO) identify the higher risk type-2 inflammatory phenotype in asthma is potentially relevant to this goal [2]. The prototype ORACLE scale based on two simple measures of type 2 airway inflammation (blood eosinophils and F ENO) quantifies the excess risk conferred by raised biomarkers that is removed by type-2 anti-inflammatory treatment in trial populations <https://bit.ly/3F1gnUl> The authors acknowledge colleagues and patients in the Oxford University Hospitals Foundation Trust's severe asthma clinic for inspiration, help and proofreading.